Domestic stock market is likely to remain volatile amid the discussion of the third wave of Corona in India. In this situation, market giants are advising traders and investors to place bets on the stocks of the pharma sector while maintaining a stock-specific perspective.
Market giants are of the opinion that due to the havoc of Covid-19 in India and all over the world, investors in the pharma sector will remain attractive and their balance sheet will be strengthened further. Market giants are of the opinion that the shares of Lupin, Cipla and Divis Lab should be bought from the perspective of 3 months now.
Avinash Gorakshakar of profitmart securities Says that at present there is no significant impact on the growing cases of corona on the market. But recently, if you look at the behavior of foreign institutional investors, then they are looking at withdrawing money from the Indian market.
He says that if there is any major negative news related to Covid-19, then it will have a big impact on the Indian markets. In such a situation, investors are advised to keep vigil and invest in selected quality stocks with strict stoploss.
He further said that in the situation when the number of new corona cases in India has crossed 4 lakhs, investors should focus on the pharma sector. It is expected that this sector will perform much better than the other sector in the next 2 to 3 months.
Avinash Gorakshakar Says that Lupin, Cipla and Divis Lab look very good at the current level. These include investment advice at current levels from a 3-month perspective. These stocks can also be included in the portfolio from a long-term perspective.
Rav Singhal of GCL securities talking on Lupine Said that Lupine has seen rapid growth recently. It is expected to rise further. This stock can be purchased at the current level. It can see a target of 1240 -1270. Keep a stop of 1122 rupees for this purchase.
Ravi singhal has Cipla and Divis Labs Talking on, said that with a stoploss of Rs 844 in Cipla, shop at the current level for a target of Rs 1044. On the other hand, Divis Labs has a buy recommendation for a target of Rs 4270 – 4440 with a stoploss of Rs 3922 around Rs 4,000.
For social media updates, we need Facebook (https://www.facebook.com/moneycontrolhindi/) And Twitter (.).